

Peter Lau

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7694255/publications.pdf>

Version: 2024-02-01

33
papers

697
citations

687363

13
h-index

580821

25
g-index

36
all docs

36
docs citations

36
times ranked

1277
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAFV600 melanoma. <i>Nature Communications</i> , 2022, 13, 1100. | 12.8 | 8 |
| 2 | Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma. <i>Cancer Immunology Research</i> , 2021, 9, 136-146. | 3.4 | 12 |
| 3 | Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer. <i>The Cochrane Library</i> , 2021, 2021, CD011220. | 2.8 | 8 |
| 4 | Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases. <i>European Journal of Cancer</i> , 2021, 156, 149-163. | 2.8 | 11 |
| 5 | Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES). , 2021, 9, e002995. | | 18 |
| 6 | INNV-08. LOW AND INTERMEDIATE GRADE GLIOMA UMBRELLA STUDY OF MOLECULAR GUIDED THERAPIES (LUMOS) STUDY. <i>Neuro-Oncology</i> , 2021, 23, vi106-vi107. | 1.2 | 0 |
| 7 | RTID-05. THE MULTI-ARM GLIOBLASTOMA AUSTRALASIA (MAGMA) TRIAL. <i>Neuro-Oncology</i> , 2021, 23, vi193-vi194. | 1.2 | 0 |
| 8 | Enhancing Adoptive Cell Transfer with Combination BRAF-MEK and CDK4/6 Inhibitors in Melanoma. <i>Cancers</i> , 2021, 13, 6342. | 3.7 | 4 |
| 9 | High-resolution MRI demonstrates that more than 90% of small intracranial melanoma metastases develop in close relationship to the leptomeninges. <i>Neuro-Oncology</i> , 2020, 22, 423-432. | 1.2 | 8 |
| 10 | A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies. <i>European Journal of Cancer</i> , 2020, 124, 15-24. | 2.8 | 31 |
| 11 | Brain metastases: lessons and challenges in the targeted therapy and immunotherapy era. <i>Journal of Thoracic Disease</i> , 2020, 12, 4527-4530. | 1.4 | 3 |
| 12 | 1079MO Progression of BRAF mutant CNS metastases are associated with a transcriptional network bearing similarities with the innate PD-1 resistant signature (IPRES). <i>Annals of Oncology</i> , 2020, 31, S733. | 1.2 | 0 |
| 13 | Activation of Canonical BMP4-SMAD7 Signaling Suppresses Breast Cancer Metastasis. <i>Cancer Research</i> , 2020, 80, 1304-1315. | 0.9 | 37 |
| 14 | FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2776-2786. | 6.4 | 42 |
| 15 | FDG-PET metabolic tumor volume in advanced melanoma treated with ipilimumab and nivolumab (ipi/nivo).. <i>Journal of Clinical Oncology</i> , 2020, 38, 10041-10041. | 1.6 | 0 |
| 16 | Regulation of PRMT5â€“MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 17990-18000. | 7.1 | 81 |
| 17 | A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy. <i>Scientific Reports</i> , 2019, 9, 1225. | 3.3 | 16 |
| 18 | Bevacizumab as a steroidâ€“sparing agent during immunotherapy for melanoma brain metastases: A case series. <i>Health Science Reports</i> , 2019, 2, e115. | 1.5 | 29 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Checkpoint Inhibitors in the Treatment of Metastatic Melanoma. , 2019, , 1-24. | | 0 |
| 20 | Factors associated with psychological distress amongst outpatient chemotherapy patients: An analysis of depression, anxiety and stress using the DASS-21. Applied Nursing Research, 2018, 40, 45-50. | 2.2 | 25 |
| 21 | A pilot study to assess the validity of the DASS-21 subscales in an outpatient oncology population. Psycho-Oncology, 2018, 27, 695-699. | 2.3 | 10 |
| 22 | Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. European Journal of Cancer, 2018, 105, 88-102. | 2.8 | 53 |
| 23 | Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses. Frontiers in Immunology, 2018, 9, 70. | 4.8 | 120 |
| 24 | Abstract P1-01-09: BMP4 suppresses the progression of breast cancer through altered expression of metastasis regulating genes. , 2018, , . | | 0 |
| 25 | Clinical and palliative care outcomes for patients of poor performance status treated with anti-programmed death-1 monoclonal antibodies for advanced melanoma. Asia-Pacific Journal of Clinical Oncology, 2017, 13, 385-390. | 1.1 | 27 |
| 26 | Optimal Selection of Targeted Therapies for Melanoma Patients. , 2016, , 169-183. | | 0 |
| 27 | Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition. Current Opinion in Immunology, 2016, 39, 30-38. | 5.5 | 23 |
| 28 | Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma. BMJ Case Reports, 2016, 2016, bcr2016217454. | 0.5 | 56 |
| 29 | Marked functional improvement after combined chemoradiotherapy for cervical spine glioblastoma causing quadriparesis in an adolescent. BMJ Case Reports, 2014, 2014, bcr2013202791-bcr2013202791. | 0.5 | 4 |
| 30 | Patients Prefer Chemotherapy on the Same Day As Their Medical Oncology Outpatient Appointment. Journal of Oncology Practice, 2014, 10, e380-e384. | 2.5 | 12 |
| 31 | Capecitabine for ER-positive versus ER-negative breast cancer. The Cochrane Library, 2014, , . | 2.8 | 1 |
| 32 | Artesunate is Ineffective in Controlling Valganciclovir-Resistant Cytomegalovirus Infection. Clinical Infectious Diseases, 2011, 52, 279-279. | 5.8 | 37 |
| 33 | The evaluation of a clinical scar scale for porcine burn scars. Burns, 2009, 35, 538-546. | 1.9 | 19 |